DrugPatentWatch Database Preview
Details for Patent: 7,635,704
Which drugs does patent 7,635,704 protect, and when does it expire?
Patent 7,635,704 protects GENVOYA, STRIBILD, and VITEKTA, and is included in three NDAs.
This patent has thirty-one patent family members in twenty-six countries.
This patent has thirty-one patent family members in twenty-six countries.
Summary for Patent: 7,635,704
| Title: | Stable crystal of 4-oxoquinoline compound |
| Abstract: | Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth- oxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2.theta.(.degree.) as measured by X-ray powder diffractmetry. |
| Inventor(s): | Satoh; Motohide (Osaka, JP), Motomura; Takahisa (Osaka, JP), Matsuda; Takashi (Osaka, JP), Kondo; Kentaro (Osaka, JP), Ando; Koji (Osaka, JP), Matsuda; Koji (Osaka, JP), Miyake; Shuji (Osaka, JP), Uehara; Hideto (Osaka, JP) |
| Assignee: | Japan Tobacco Inc. (Tokyo, JP) |
| Application Number: | 11/133,471 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Dosage form; Use; |
Drugs Protected by US Patent 7,635,704
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | GENVOYA | cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 207561-001 | Nov 5, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | TREATMENT OF HIV INFECTION | ➤ Sign Up | ||
| Gilead Sciences Inc | STRIBILD | cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate | TABLET;ORAL | 203100-001 | Aug 27, 2012 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | Y | TREATMENT OF HIV INFECTION | ➤ Sign Up | ||
| Gilead Sciences Inc | VITEKTA | elvitegravir | TABLET;ORAL | 203093-001 | Sep 24, 2014 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | TREATMENT OF HIV INFECTION | ➤ Sign Up | ||
| Gilead Sciences Inc | VITEKTA | elvitegravir | TABLET;ORAL | 203093-002 | Sep 24, 2014 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | TREATMENT OF HIV INFECTION | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Foreign Priority and PCT Information for Patent: 7,635,704
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2004-150979 | May 20, 2004 |
Non-Orange Book US Patents Family Members for Patent 7,635,704
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,981,103 | Stable crystal of 4-oxoquinoline compound | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Family Members for US Patent 7,635,704
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 049280 | ➤ Sign Up | |||
| Argentina | 096100 | ➤ Sign Up | |||
| Australia | 2005245296 | ➤ Sign Up | |||
| Brazil | PI0510114 | ➤ Sign Up | |||
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
